

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/004395-2021>

Contract

Human Leucocyte Antigen (HLA) specific Antibody detection and definition systems

NHS Blood & Transplant

F03: Contract award notice

Notice identifier: 2021/S 000-004395

Procurement identifier (OCID): ocds-h6vhtk-029880

Published 4 March 2021, 10:56pm

Section I: Contracting authority

I.1) Name and addresses

NHS Blood & Transplant

North Bristol Park

Filton, Bristol

BS34 7QH

Email

marta.drozdowska@nhsbt.nhs.uk

Country

United Kingdom

NUTS code

UK - UNITED KINGDOM

Internet address(es)

Main address

www.nhsbt.nhs.uk

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Human Leucocyte Antigen (HLA) specific Antibody detection and definition systems

Reference number

NHSBT1249

II.1.2) Main CPV code

- 38434540 - Biomedical equipment

II.1.3) Type of contract

Supplies

II.1.4) Short description

Histocompatibility & Immunogenetics (H&I) is a strategic business function of NHS Blood and Transplant (NHSBT) that provides a portfolio of testing and advice which supports the diagnosis and/ or treatment of a variety of medical conditions in the following clinical areas:

- Solid organ transplantation and clinical advice for donor selection

- Haematopoietic stem cell transplantation and clinical advice for donor selection
- Blood transfusion and transfusion reactions (SHOT)
- Platelet refractoriness and provision of HLA/ HPA selected components
- Platelet immunology
- Granulocyte immunology
- Immunogenetics including diagnostic testing and pharmacogenetics
- Haematopoietic stem cell donor registry typing

NHSBT require Human Leukocyte Antigen (HLA) antibody detection and definition systems. This is to ensure compatibility between donors and recipients of HLA selected platelets, haematopoietic stem cells for transplantation and solid organ transplantation (renal, liver and cardiothoracic). We must be able to perform HLA antibody detection and definition in an efficient, timely and cost effective manner to meet the demands and expectations of our customers and the patients we serve.

We will work with the successful suppliers to realise this ambition and to perform HLA rapid typing in an efficient, timely and cost effective manner to meet the demands and expectations of our customers and the patients we serve.

For NHSBT these services are supplied through a national network of six laboratories located at Birmingham, Bristol, Colindale, Newcastle, Sheffield and Tooting. Scottish National Blood Transfusion Service (SNBTS) and Welsh Blood Service (WBS) are allowed to utilise this agreement.

The Framework Agreement was awarded for 4 years and divided into lots as follows:

Lot 1 - HLA Antibody Detection and Definition Systems - awarded to VH Bio Ltd and Immucor

Lot 2 - Maintenance of Existing Luminex Systems - awarded to Immucor

II.1.6) Information about lots

This contract is divided into lots: Yes

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £7,143,000

II.2) Description

II.2.1) Title

HLA Antibody Detection and Definition Systems

Lot No

1

II.2.2) Additional CPV code(s)

- 33100000 - Medical equipments
- 33140000 - Medical consumables
- 33141625 - Diagnostic kits
- 38434540 - Biomedical equipment
- 50421000 - Repair and maintenance services of medical equipment

II.2.3) Place of performance

NUTS codes

- UK - UNITED KINGDOM

II.2.4) Description of the procurement

Histocompatibility & Immunogenetics (H&I) is a strategic business function of NHS Blood and Transplant (NHSBT) that provides a portfolio of testing and advice which supports the diagnosis and/ or treatment of a variety of medical conditions in the following clinical areas:

- Solid organ transplantation and clinical advice for donor selection
- Haematopoietic stem cell transplantation and clinical advice for donor selection
- Blood transfusion and transfusion reactions (SHOT)
- Platelet refractoriness and provision of HLA/ HPA selected components
- Platelet immunology

- Granulocyte immunology
- Immunogenetics including diagnostic testing and pharmacogenetics
- Haematopoietic stem cell donor registry typing

NHSBT require Human Leukocyte Antigen (HLA) antibody detection and definition systems. This is to ensure compatibility between donors and recipients of HLA selected platelets, haematopoietic stem cells for transplantation and solid organ transplantation (renal, liver and cardiothoracic). We must be able to perform HLA antibody detection and definition in an efficient, timely and cost effective manner to meet the demands and expectations of our customers and the patients we serve.

We will work with the successful suppliers to realise this ambition and to perform HLA rapid typing in an efficient, timely and cost effective manner to meet the demands and expectations of our customers and the patients we serve.

For NHSBT these services are supplied through a national network of six laboratories located at Birmingham, Bristol, Colindale, Newcastle, Sheffield and Tooting. Scottish National Blood Transfusion Service (SNBTS) and Welsh Blood Service (WBS) are allowed to utilise this agreement.

The Framework Agreement was awarded for 4 years and divided into lots as follows:

Lot 1 - HLA Antibody Detection and Definition Systems - awarded to VH Bio Ltd and Immucor

Lot 2 - Maintenance of Existing Luminex Systems - awarded to Immucor

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Maintenance of Existing Luminex Systems

Lot No

2

II.2.2) Additional CPV code(s)

- 50421000 - Repair and maintenance services of medical equipment

II.2.3) Place of performance

NUTS codes

- UK - UNITED KINGDOM

II.2.4) Description of the procurement

Histocompatibility & Immunogenetics (H&I) is a strategic business function of NHS Blood and Transplant (NHSBT) that provides a portfolio of testing and advice which supports the diagnosis and/ or treatment of a variety of medical conditions in the following clinical areas:

- Solid organ transplantation and clinical advice for donor selection
- Haematopoietic stem cell transplantation and clinical advice for donor selection
- Blood transfusion and transfusion reactions (SHOT)
- Platelet refractoriness and provision of HLA/ HPA selected components
- Platelet immunology
- Granulocyte immunology
- Immunogenetics including diagnostic testing and pharmacogenetics
- Haematopoietic stem cell donor registry typing

NHSBT require Human Leukocyte Antigen (HLA) antibody detection and definition systems. This is to ensure compatibility between donors and recipients of HLA selected platelets, haematopoietic stem cells for transplantation and solid organ transplantation (renal, liver and cardiothoracic). We must be able to perform HLA antibody detection and definition in an

efficient, timely and cost effective manner to meet the demands and expectations of our customers and the patients we serve.

We will work with the successful suppliers to realise this ambition and to perform HLA rapid typing in an efficient, timely and cost effective manner to meet the demands and expectations of our customers and the patients we serve.

For NHSBT these services are supplied through a national network of six laboratories located at Birmingham, Bristol, Colindale, Newcastle, Sheffield and Tooting. Scottish National Blood Transfusion Service (SNBTS) and Welsh Blood Service (WBS) are allowed to utilise this agreement.

The Framework Agreement was awarded for 4 years and divided into lots as follows:

Lot 1 - HLA Antibody Detection and Definition Systems - awarded to VH Bio Ltd and Immucor

Lot 2 - Maintenance of Existing Luminex Systems - awarded to Immucor

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number: [2019/S 231-565906](#)

Section V. Award of contract

Contract No

NHSBT1249

Lot No

1

Title

HLA Antibody Detection and Definition Systems

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

22 February 2021

V.2.2) Information about tenders

Number of tenders received: 3

The contract has been awarded to a group of economic operators: Yes

V.2.3) Name and address of the contractor

Immucor

Solihull

Country

United Kingdom

NUTS code

- UK - UNITED KINGDOM

The contractor is an SME

Yes

V.2.3) Name and address of the contractor

VH Bio Ltd

Gateshead

Country

United Kingdom

NUTS code

- UK - UNITED KINGDOM

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £7,020,000

Section V. Award of contract

Contract No

NHSBT1249

Lot No

2

Title

Maintenance of Existing Luminex Systems

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

1 March 2021

V.2.2) Information about tenders

Number of tenders received: 2

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Immucor

Solihull

Country

United Kingdom

NUTS code

- UK - UNITED KINGDOM

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £123,000

Section VI. Complementary information

VI.4) Procedures for review

VI.4.1) Review body

NHS Blood and Transplant

Bristol

Country

United Kingdom